Rising young researchers in cancer research are advancing innovative strategies in drug development. Their approaches include using nanoparticles that adhere to cells and drugs activated by X-rays to enhance radiotherapy effects. Notably, Namhee Kim, a computational biologist at Biorevert, is focusing on "cancer reversion" to reprogram malignant cells to benign states, reducing reliance on chemotherapy. By creating algorithms to simulate biological interactions, Kim and her team are identifying molecular targets that could help revert lung cancer cells back to a non-aggressive form, a significant leap in cancer treatment methodologies.
As a computational biologist at biotechnology start-up Biorevert in Daejeon, South Korea, Kim is hunting for molecular switches that can induce cancer reversion.
It's a very powerful way to research cancer and is very fascinating to me, says Kim, who is developing algorithms from large data sets to simulate interactions.
Collection
[
|
...
]